European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

Trump's recent announcement that he's procured $7 trillion in incoming investments to the U.S. may very well have been an underestimate.

Novartis appoints Karen Hale as chief legal and compliance officer: Basel Tuesday, April 1, 2025, 13:00 Hrs [IST] Novartis announced the appointment of Karen Hale to the expanded ...

“Therefore, I decided to accept a new role as CEO of a US-based biotech. I want to thank [CEO Vas Narasimhan] for the opportunity to work at this great company and to everyone in oncology for ...

Novartis says Cosentyx could be used as an early intervention in psoriasis after new data suggests it is the first drug of its kind to modify the course of the disease. The Swiss big pharma ...

Under the leadership of CEO Vas Narasimhan, who took over in 2018, the company has focused on using digital technology to engage with both patients and doctors. In a conference call outlining the ...

Vas Narasimhan, that the filing could be held back until 2027 or even longer. Novartis revealed in its third-quarter results update that it had taken an $800 million charge related to the ...

and is another problem for Novartis chief executive Vas Narasimhan to tackle as he tries to restore the firm’s reputation. The FDA revealed earlier this month that it may take action against ...